The emerging recognition that certain microbes function as cancer drivers represents a paradigm shift in oncology, moving beyond traditional genetic models to embrace microbial contributions to tumorigenesis. This understanding opens new avenues for both prevention and treatment strategies targeting pathogenic bacteria rather than solely focusing on tumor cells themselves. Fusobacterium nucleatum exemplifies this microbial-cancer connection through its dual nature as both oral commensal and systemic pathogen. Originally residing in healthy oral microbiomes, this bacterium can migrate to distant body sites including the intestinal tract, where it assumes pathogenic roles. The organism's cancer-promoting capabilities operate through multiple coordinated mechanisms: deployment of specific virulence factors that directly damage host tissues, sustained inflammatory responses that create tumor-favorable environments, sophisticated immune evasion strategies that prevent clearance, and direct molecular interactions with cancer cells that enhance their malignant properties. The bacterium shows particularly strong associations with colorectal cancer progression, though its influence extends to other malignancies and inflammatory conditions including periodontal disease and inflammatory bowel disease. This multi-system pathogenicity suggests F. nucleatum represents more than an opportunistic infection—it appears to be an active contributor to disease progression across anatomical sites. The clinical implications are substantial, as detection methods for this pathobiont could serve as diagnostic biomarkers for cancer risk or progression. More intriguingly, therapeutic strategies targeting F. nucleatum through antimicrobials or immune modulation might complement traditional cancer treatments, potentially improving outcomes for patients harboring this problematic microbe.